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ABSTRACT 
 
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by 
impairment of memory and, eventually, by disturbances in cognitive abilities. Brain regions 
crucial for learning and memory exhibit atrophy, but the underlying mechanisms for 
neurodegeneration continues to be point of debate. One fundamental abnormality that 
certainly plays a pivotal role is altered proteolytic processing of the amyloid precursor protein 
(APP) such that toxic amyloid-β (Aβ) peptides are formed. To prevent aggregation, enhance 
clearance or preclude formation of Aβ represent notable attempted strategies in the fight 
against AD. Because none of these strategies have - as of yet - proved triumphant, there is a 
persistent demand for understanding basic biological features of cells in an AD state. In this 
regard, this thesis collectively aims to uncover mechanisms which regulate processing and 
trafficking of APP and APP-relevant molecules.  
 
Paper 1 aims to expand our understanding of endogenous APP transport to synapses of 
hippocampal neurons. Using immunocytochemical approaches, we find that under normal 
physiological conditions, APP primarily exists as cleaved fragments at nerve terminals. 
Perturbation of BACE1 activity, either through genetic manipulation or pharmacological 
inhibition, enhanced accumulation of APP at presynaptic terminals. Together with 
biochemical observations, this finding suggests the existence of a full-length APP trafficking 
pathway in neurons. Moreover, it raises questions on whether strong perturbation of BACE1 
activity may be deleterious for synaptic function.  
 
Paper 2 aims to elucidate how a protein involved in protein sorting and membrane 
trafficking, SNX3, may be involved in APP processing and Aβ generation. An in vitro cell 
culture model involving genetically manipulated expression of SNX3 was used in 
conjunction with a number of immunocytochemical techniques, flow cytometry and 
biochemical approaches to fulfill this aim. We found that SNX3 overexpression can perturb 
physical interaction of APP and BACE1 such that it results in decreased Aβ levels. This was 
likely the result of reduced APP internalization from the surface of cells. As such, SNX3 
regulates Aβ production by influencing APP endocytosis. 
 
Paper 3 aims to understand how exercise can lessen Aβ accumulation and how BDNF may 
be involved in associated regulation of APP processing. Using a transgenic mouse model of 
AD and cultured human neural cells, we demonstrate that exercise and BDNF can reduce 
production of toxic Aβ peptides through a mechanism involving enhanced α-secretase 
activity. Flow cytometry, biochemical techniques and immunocytochemistry enabled us to 
determine that this anti-amyloidogenic APP processing involves subcellular redistribution of 
α-secretase and an increase in intracellular neuroprotective APP peptides capable of binding 
and inhibiting BACE1. Exercise, and other factors which enhance BDNF signaling, may - 
therefore - have both therapeutic and prophylactic potential in AD.  
 
Paper 4 aims to determine the contribution of extracellular vesicles (EVs) to Aβ production 
and pathogenesis of AD. Using EVs isolated from cerebrospinal fluid and plasma of AD 
patients, plasma of AD mouse models and media of cultured neural cells expressing AD 
mutations, we determined that EVs have the capacity to destabilize neuronal Ca2+ 
homeostasis, impair mitochondrial function and sensitize neurons to excitotoxicity. Though 
it was found that EVs contain relatively low levels of Aβ species, the ratio between more 
toxic Aβ42 isoforms and Aβ40 was enhanced. The majority of this Aβ appeared to be on the 
surface of EVs and this appeared to be an important feature in the transcellular spread of Aβ 
and associated toxicity.  
 
In summary, this thesis expands our understanding of mechanisms which regulate processing 
and trafficking of APP and APP-relevant molecules. In doing so, the work presented here 
collectively advocates for novel strategies in the fight against AD.  
 
  
  
POPULAR SCIENCE SUMMARY 
 
English 
 
If moments are purely transient, then our memories are permanent. Forming an integral core 
of our relationships with one another, memories are part of the very essence of consciousness. 
Heartbreaking is the theft of these memories, and Alzheimer’s Disease a menacing culprit. 
200 drugs over the last 30 years have failed to solve the disease pushing scientists further and 
further with each passing year. Though these memories may be locked away, uplifting is the 
thought that a key exists somewhere out there. Herein, I present my attempts to contribute to 
the field of Alzheimer’s Disease (AD) research with the sincere hope of finding keys for 
those who need it most. 
 
The complexity of the disease has puzzled many and a litany of open questions remain to be 
answered. The death of cells in brain regions responsible for learning and memory are 
considered a critical event in AD. Though the driving force of this cell death may be unclear, 
the disease is characterized by the deposition of plaques in the brain. The plaques themselves 
are formed from a protein, called the amyloid precursor protein (APP), which can be cleaved 
in either a non-toxic or toxic plaque-forming fashion. To identify players which determine 
whether APP is destined to go down the toxic or non-toxic path is the overarching subject of 
this thesis.  
 
Paper 1 lays down the foundation by examining the connections between brain cells in the 
context of APP cleavage. Because loss of these connections between brain cells are thought 
to be an important event in AD, we sought to understand whether the APP molecule is 
natively transported to the connection sites. Paper 2 builds on this work by investigating a 
novel protein that regulates molecular transport within the cell and is capable of controlling 
whether APP travels down the toxic or non-toxic path. Should the protein enter the path 
producing toxic products, the cell has clear instructions and abilities to degrade the toxic 
products. In the event of dysfunctional degradation or overload of the degradation system, 
the toxic products can be transported out of the cell through microscopic extracellular 
vesicles. Paper 4 aims to enhance our understanding of these extracellular vesicles and how 
they may contribute to brain cell loss in AD. Indeed, they appear to be toxic to neighboring 
cells. The ultimate goal of research should be to find effective treatments for patients. In this 
regard, Paper 3 proposes that exercise may be a suitable strategy because it destines APP for 
the non-toxic pathway.  
 
Cumulatively, this work enhances our understanding of events involved in AD whilst 
providing novel approaches in the fight against it. Impossible is nothing. 
 
Hindi 
 
ये पल तो क्षणभंगुर हैं, मगर हमारी सृ्मततयााँ  स्थायी हैं. हमारे पारस्पररक सम्बन्ो ंका अतभन्न अंग हैं ये 
सृ्मततयााँ और हमारी चेतना का मूलतत्व हैं. इन सृ्मततयो ंका तिन जाना हृदयतिदारक है और इसका 
अपराधी है Alzheimer’s रोग. तपिले 30 िर्षों में लगभग 200 और्षतधयां भी इस रोग का तनिारण करने 
में असफल रही हैं और हर िर्षष िैज्ञातनको ंपर इस समस्या का समाधान पाने का दबाि बढ़ता जा रहा है. 
यद्यतप हमारी सृ्मतत तो स्थायी है, सुरतक्षत है, और कही ंपर तो होगा इस रोग का तनिारण – यही आशा  है 
मेरी शोध की पे्ररणा का स्रोत. और इस भरोसे के साथ तक ऐसे तकसी तनिारण को ढूाँढ़ने में कुि योगदान 
दे सकूाँ , अब मैं आपके सामने प्रसु्तत कराँ गा Alzheimer’s रोग से जुडी मेरी स्वयं की शोध और उसके 
पररणाम. 
 
इस रोग की जतिलता ने बहुतो ंको हैरान तकया है और बहुत से प्रश्न अभी भी अनुत्तररत हैं. Alzheimer’s 
रोग के होने में महत्वपूणष भूतमका है मस्तस्तष्क के उन भागो ंकी कोतशकाओ ंके नष्ट हो जाने की तजन पर 
सीखने और स्मरण रखने का दातयत्व है. यद्यतप  इन कोतशकाओ ंके नष्ट हो जाने का कारण पूरी तरह से 
ज्ञात नही ंहै, लेतकन मस्तस्तष्क में एक तचपतचपे रासायतनक प्रोिीन का जमा हो जाना इस रोग का लक्षण 
है. इस प्रोिीन का नाम है amyloid precursor protein (APP) और यह तिरै्षले या गैर तिरै्षले दोनो ं
रप में तिभातजत हो सकती है. उन तत्वो ंकी पहचान करना,  तजनसे यह तनतित होता है  तक APP का 
तिभाजन तिरै्षला होगा या गैर तिरै्षला, ही  इस शोध का तिर्षय है. 
 
पहले शोध पत्र से नीिं डाली गई है मस्तस्तष्क की तितभन्न कोतशकाओ ंकी  पारस्पररक कतडयो ं को APP 
के तिभाजन के पररपे्रक्ष्य में समझने की. चंूतक  इन कतडयो ंके तिचे्छद को Alzheimer’s रोग में एक 
महत्वपूणष घिना माना जाता है, हमने यह समझने का प्रयास तकया है तक क्या APP अणु का पररिहन 
इन कतडयो ंसे सम्बद्ध भागो ं तक होता है.  दूसरे शोध पत्र में एक ऐसी नई प्रोिीन पर अनुसन्ान तकया 
गया है जोतक कोतशकाओ ंके अन्दर आणतिक पररिहन को तनयस्तित करती है और तजसमें क्षमता है 
तनयंत्रण करने की तक APP तिरै्षले मागष पर अग्रसर होती है या गैर तिरै्षले मागष पर. यतद APP अत्यतधक 
  
मात्रा में तिरै्षले तत्व का उत्पादन करने लगे तो उसे अतत सूक्ष्म नतलकाओ ंके द्वारा कोतशका से बाहर 
तनकाला जा सकता है. चौथे शोध पत्र का तिर्षय है इन अतत सूक्ष्म नतलकाओ ंके बारे में और ज्ञान अतजषत 
करना और समझना तक इनकी भूतमका मस्तस्तष्क की कोतशकाओ ंके नष्ट होने में क्या हो सकती है. ये 
आस-पास की कोतशकाओ ंके तलए तिरै्षली प्रतीत होती हैं. इस शोध का आधारभूत लक्ष्य है रोतगयो ंके 
तलए प्रभािी उपचार ढूाँढ़ना. इस सन्दभष में, तीसरे शोध पत्र में सुझाि तदया गया है तक Alzheimer’s रोग 
की रोकथाम में व्यायाम एक उतचत रणनीतत हो सकती है क्योतंक यह APP को गैर तिरै्षले मागष की ओर 
तनदेतशत करता है. 
 
इन सभी पहलुओ ंको ध्यान में रखते हुए, मेरी शोध Alzheimer’s रोग से जुडी प्रतियाओ ंके हमारे ज्ञान 
को और आगे बढ़ाती है और हमें इसकी रोकथाम और तनिारण की तदशा में कुि नए रासे्त तदखाती है. 
िैसे भी असम्भि कुि भी नही ंहै. 
 
Swedish 
 
Även om stunder är övergående, så är våra minnen permanenta. De bildar kärnan av våra 
relationer med varandra och är en väsentlig del av vårt medvetande. Förlust av dessa minnen 
är alltid sorglig och Alzheimers sjukdom är ofta skyldig. 200 olika läkemedel har under de 
senaste 30 åren misslyckats med att finna lösningen på denna sjukdom, vilket driver forskare 
längre och längre bort för varje år. Även om dessa minnen kan vara låsta är tanken att en nyckel 
finns någonstans där ute upplyftande. Här presenterar jag mina försök att bidra till Alzheimer 
(AD) forskningen med ett ärligt hopp att finna lösningar för patienterna som behöver dem mest. 
 
Sjukdomens komplexitet har förvirrat många och ett antal öppna frågor kvarstår att besvara. 
Död av celler i hjärnregioner ansvariga för lärande och minne anses vara en kritisk händelse i 
AD. Även om skälet för denna celldöd kan vara oklar, kännetecknas sjukdomen av deponering 
av plack i hjärnan. Placken bildas av ett protein, som kallas Amyloid Prekursor Protein (APP), 
vilket kan klyvas på antingen ett icke-toxiskt eller ett toxiskt, plackbildande sätt. Att identifiera 
faktorer som avgör om APP är avsett att följa den toxiska eller icke-toxiska vägen är det 
övergripande ämnet för denna avhandling. 
 
Artikel 1 lägger grunden genom att undersöka kopplingarna mellan hjärnceller i samband med 
APP-klyvning. Eftersom förlusten av dessa kopplingar mellan hjärnceller anses vara en viktig 
händelse i AD, försökte vi klarlägga om APP-molekylen transporteras till anslutningsställena. 
Artikel 2 bygger på detta arbete genom att undersöka ett nytt protein som reglerar transporten 
av molekyler inom cellen och kan kontrollera om APP tar den toxiska eller icke toxiska vägen. 
Om proteinet kommer in på vägen som producerar toxiska produkter, har cellen tydliga 
instruktioner och kapacitet att bryta ner dessa produkter. I händelse av dysfunktionell 
nedbrytning eller överbelastning av nedbrytningssystemet kan de toxiska produkterna 
transporteras ut ur cellen via mikroskopiska extracellulära vesiklar. Artikel 4 syftar till att 
förbättra vår förståelse av dessa extracellulära vesiklar och hur de kan bidra till hjärncellsförlust 
i AD. Faktum är att de verkar vara toxiska för närliggande celler. Det ultimata målet med AD 
forskning bör vara att hitta effektiva behandlingar för patienter. I detta avseende föreslår artikel 
3 att träning kan vara en lämplig strategi eftersom den kan driva APP att klyvas via den icke-
toxiska vägen. 
 
Kumulativt förbättrar detta arbete vår förståelse av händelser som är inblandade i AD samtidigt 
som det indikerar nya tillvägagångssätt i kampen mot denna sjukdom. Inget är omöjligt. 
 
  
  
LIST OF SCIENTIFIC PAPERS 
I. Nigam S. M., Xu S., Ackermann F., Gregory J. A., Lundkvist J., Lendahl U., 
Brodin L. (2016) Endogenous APP accumulates in synapses after BACE1 
inhibition. Neurosci. Res. 109, 9–15. 
II. Xu S., Nigam S. M., Brodin L. Overexpression of SNX3 decreases amyloid-β 
peptide production by reducing endocytosis of amyloid precursor protein. 
Manuscript. 
III. Nigam S. M., Xu S., Kritikou J. S., Marosi K., Brodin L., Mattson M. P. (2017) 
Exercise and BDNF reduce Aβ production by enhancing α-secretase 
processing of APP. J. Neurochem. 38, 42–49. 
IV. Eitan E., Hutchison E. R., Marosi K., Comotto J., Mustapic M., Nigam S. M., 
Suire C., et al. (2016) Extracellular vesicle-associated Aβ mediates trans-
neuronal bioenergetic and Ca2+-handling deficits in Alzheimer’s disease 
models. Npj Aging Mech. Dis. 2, 16019. 
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Alzheimer’s Disease .............................................................................................. 1 
1.2 Neuropathological Basis of AD ............................................................................ 2 
1.2.1 History ....................................................................................................... 2 
1.2.2 The Amyloid Cascade Hypothesis ........................................................... 2 
1.3 Amyloid Precursor Protein .................................................................................... 3 
1.3.1 Amyloid Precursor Protein Processing ..................................................... 4 
1.3.2 Subcellular Trafficking of APP ................................................................ 8 
1.3.3 Extracellular Vesicles ............................................................................... 9 
1.3.4 Synapses .................................................................................................. 10 
1.3.5 SNX Family of proteins .......................................................................... 11 
1.3.6 Subcellular Trafficking of APP-relevant Secretases .............................. 11 
1.4 Genetics ............................................................................................................... 13 
1.5 Alternatives to the Amyloid Cascade Hypothesis .............................................. 14 
1.5.1 Tau Hypothesis ........................................................................................ 14 
1.5.2 Oxidative Stress Hypothesis ................................................................... 15 
1.5.3 Inflammation Hypothesis ........................................................................ 15 
1.5.4 Other Hypotheses .................................................................................... 16 
1.6 Treatment strategies ............................................................................................ 16 
1.6.1 Exercise ................................................................................................... 18 
1.6.2 BDNF ...................................................................................................... 19 
2 Aims ............................................................................................................................... 21 
2.1 Paper 1 ................................................................................................................. 21 
2.2 Paper 2 ................................................................................................................. 21 
2.3 Paper 3 ................................................................................................................. 21 
2.4 Paper 4 ................................................................................................................. 21 
3 Results and discussion ................................................................................................... 23 
3.1 Paper 1 ................................................................................................................. 23 
3.2 Paper 2 ................................................................................................................. 25 
3.3 Paper 3 ................................................................................................................. 27 
3.4 Paper 4 ................................................................................................................. 29 
4 Conclusions and Future Perspectives ........................................................................... 33 
5 Acknowledgements ....................................................................................................... 35 
6 References ..................................................................................................................... 39 
 
  
  
LIST OF ABBREVIATIONS 
AD Alzheimer’s disease 
ADAM A disintegrin and metalloproteinase 
ADP Adenosine diphosphate 
AICD Amino-terminal APP intracellular domain 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
APLP APP-like proteins 
APOΕ Apolipoprotein E 
APP Amyloid precursor protein 
ARF6 GTPase ADP ribosylation factor 6 
Aβ Amyloid β 
BACE1 β-site amyloid precursor protein cleaving enzyme 1 
BBS α-bungarotoxin-binding site 
BDNF Brain derived neurotrophic factor 
BiFC Bimolecular fluorescence complementation 
CaMK2 Ca2+/calmodulin-dependent protein kinase II 
CNS Central Nervous System 
CSF Cerebrospinal fluid 
CTF C-terminal fragment 
DNA Deoxyribonucleic acid 
ELISA Enzyme-linked immunosorbent assay 
EMA European Medicines Agency 
ER Endoplasmic reticulum 
EV Extracellular vesicle 
FAD Familial Alzheimer’s disease  
FDA Food and Drug Administration 
GGA Golgi-localized, gamma adaptin ear-containing, ARF-binding 
GTPase Guanosine triphosphate hydrolase 
HEK293T Human embryonic kidney cells 293T 
IL-1 Interleukin-1 
LTD Long-term depression 
LTP Long-term potentiation 
MAPK Mitogen-activated protein kinase 
miRNA Micro ribonucleic acid 
mRNA Messenger ribonucleic acid 
MVB Multivesicular bodies 
NMDA N-Methyl-D-aspartic acid 
PET Positron emission tomography 
PLA Proximity ligation assay 
ROS Reactive oxygen species 
rRNA Ribosomal ribonucleic acid 
sAPP Soluble amyloid precursor protein 
SNX Sorting Nexin 
SV2 Synaptic vesicle glycoprotein 2A 
TGN Trans Golgi network 
  1 
1 INTRODUCTION 
 
The quest for extending longevity has captivated the imagination of mankind - markedly 
unrestricted by cultural boundaries - over the last several millennia. These anti-aging ambitions 
can be illustrated by the development of innumerable myths on how we can achieve 
immortality. Indeed, the ‘Fountain of Youth’, ‘Elixir of Life’, religious nirvana and snake oil 
are just a small subset of our collective efforts. Though inspiring, these mythological potions 
and practices proved fruitless as the average life expectancy generally remained below 40 years 
of age for much of human history. Our big breakthrough came instead by way of advances in 
healthcare and sanitation in the 20th century. While the ensuing explosion in worldwide life 
expectancy amounts to a current figure crossing the 70 year mark, this trend is not without 
some caveats. Generally, our ancestors rarely suffered from conditions like heart disease, 
cancer and loss of mental function - conditions which are all too common presently. It seems, 
thusly, that while we have pushed the bounds of human longevity we have also ushered in a 
basket of new challenges. Alzheimer’s Disease - being intimately linked to aging - is one such 
condition that has and will continue to test scientists, caregivers and families as we voyage into 
the 21st century. Here I present my scientific efforts to contribute to the ever-expanding 
Alzheimer's Disease research field with the ultimate goal of aiding individuals and families 
afflicted by this devastating disease.  
 
1.1 ALZHEIMER’S DISEASE 
 
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that leads to a variety 
of symptoms that are heavily relied upon for diagnosis. The symptoms - which are also 
progressively detrimental in nature - begin with memory problems, confusion and reduced 
concentration, and can eventually manifest in the form of severe memory deficits, difficulties 
in speaking, motor impairment, anxiety, paranoia and other cognitive disabilities. In the final 
stages of the disease, patients are completely reliant on caregivers for management of both their 
physical and mental well-being. The costs associated with caregiving as well as medicinal 
treatment are projected to pose a great challenge to society as our global population ages and 
prevalence of the disease increases. Indeed, the US-based Alzheimer’s Association estimates 
that around 5 million Americans are living with the condition presently (in 2017) amounting 
to over $250 billion in care costs. By 2050, the organization predicts that both of these figures 
will more than triple in the US alone. This threat reverberates across the globe. By 2050, over 
150 million individuals worldwide are expected to face the progressive and ultimately fatal 
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condition1. With such dire predicted outcomes and an absence of effective treatments, 
governments, research institutions, healthcare providers and biopharmaceutical companies are 
mounting a concerted effort to understand and manage the disease2.  
 
1.2 NEUROPATHOLOGICAL BASIS OF AD 
 
1.2.1 History 
 
In 1906, the world was introduced to the case of Auguste Deter. Physician Alois Alzheimer 
described his 50-year old female patient as experiencing progressive sleep and memory 
disturbances, aggression and confusion. The report initially generated little interest among 
psychiatrists and neuropathologists of the time, but Alzheimer persisted in his characterization 
of the peculiar condition. After an autopsy of the patient was conducted, Alzheimer managed 
to perform both morphological and histological investigations of Deter’s brain. In addition to 
general brain atrophy, he noted alterations that would later be described as senile plaques and 
neurofibrillary tangles. Together, these alterations would constitute the classical hallmarks of 
Alzheimer’s Disease. For much of the 20th century, the Alzheimer name remained in relative 
obscurity until a resurgent prevalence of the disease prompted renewed interest in investigating 
its neuropathological basis. 
 
Our understanding of AD has since expanded to incorporate the notion that AD is a 
multifactorial disease. In addition to plaques and tangles, patients may be plagued with a 
number of pathologies including microgliosis, astrocytosis, neuritic dystrophy, neuronal loss 
and synaptic insufficiencies3. The search for a key regulator and comprehensive hypothesis of 
these events began in the 1980s - ultimately leading to the development of the “amyloid cascade 
hypothesis”4. 
 
1.2.2 The Amyloid Cascade Hypothesis 
 
Much of the AD research community has focused on senile plaques as the key player in 
pathogenesis. In 1984, the Amyloid-β (Αβ) protein was identified to be the core constituent of 
the senile plaques5. The ensuing “amyloid cascade hypothesis” became the dominant theory 
for the mechanism of AD pathogenesis. The hypothesis holds that Aβ is the causative agent in 
AD and lies upstream to other observed pathologies like neurofibrillary tangles, cell loss, 
vascular damage and dementia4. Aβ peptides can range from 38 to 43 amino acids in length6 
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with the most abundant species being Aβ40 and Αβ42. Importantly, Aβ42 has a hydrophilic 
structure which makes it particularly prone to aggregation and subsequent plaque deposition7. 
As such, an imbalance in Aβ production favoring the Aβ42 form is viewed as a marker for 
toxicity. While our understanding of this protein has expanded considerably over the last 30 
years, a complete picture remains enigmatic. As a result, the amyloid cascade hypothesis has 
been challenged based on the following observations: 
 
 Amyloid plaque burden is a relatively poor correlate of cognitive impairment  
 Aβ deposits can be found in post-mortem brain of non-demented individuals 
 Neurofibrillary tangles can be observed prior to plaque deposits  
 
Notably, these challenges focus on plaque deposits and overlook the contribution of diffuse 
plaques and/or pre-plaque forms of Aβ (e.g. oligomeric Aβ). A comprehensive point/counter-
point can be reviewed elsewhere8, but it is important to note that several lines of evidence 
indicate that Aβ is tightly linked to the degeneration observed in AD: 
 
 Genetic mutations resulting in altered Aβ levels are invariably connected to AD 
(discussed in section 1.4) 
 Aβ42 oligomers can decrease synapse density, inhibit LTP, enhance LTD and impair 
memory 
 Aβ oligomers can induce hyperphosphorylation of tau 
 
These and other lines of evidence cumulatively provide a strong basis for continued research 
within the realm of the amyloid cascade hypothesis. Accordingly, the present thesis focuses on 
upstream events that precede plaque formation - namely the proteolytic processing of the 
Amyloid Precursor Protein (APP), which can produce Aβ.  
 
1.3 AMYLOID PRECURSOR PROTEIN 
 
Discovered in 19879 as a precursor to Aβ, the Amyloid Precursor Protein (APP) is a type-1 
transmembrane protein with a large N-terminal domain, a single transmembrane region and a 
short C-terminal domain. The protein belongs to a gene family that is evolutionarily conserved 
across multiple species including C. elegans, drosophila melanogaster and mammals. While 
multiple isoforms of mammalian APP have been identified (e.g. 695-, 751-, 770-amino acids) 
and are ubiquitously expressed, there appears to be a preference for specific isoforms across 
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cell types. Cells of neuronal origin, for instance, express primarily the 695-amino acid 
isoform10. The normal functions of APP are not fully understood, but evidence suggests a role 
in neuronal survival, neurite outgrowth, synaptic plasticity and cell adhesion11.  
 
Importantly, there are also two APP homologues, termed APP-like proteins, that are expressed 
in the nervous system: APLP-1 and APLP-2. Both share domain structure similarity with APP 
and appear to have some redundant functions. Transgenic mice with single knockouts of either 
APP(-/-)12, APLP-1(-/-)13 or APLP-2(-/-)14 do not exhibit any severe phenotypes. Interestingly, 
mice with double-knockouts of APP(-/-)/APLP-1(-/-) are viable, but APP(-/-)/APLP-2(-/-) 
knockout is lethal. As such, there may be a key role for APLP-2 in embryonic development13. 
Moreover, proteolytic processing of APLP-1 and APLP-2 can occur by the same secretases 
which process APP and result in similar products15 (although only APP is capable of generating 
an amyloidogenic fragment16). These findings naturally complicate the process of finding a 
treatment for AD as non-APP targets must be considered during the drug development process. 
 
1.3.1 Amyloid Precursor Protein Processing 
 
In neuronal cells, two distinct pathways - termed the non-amyloidogenic and amyloidogenic 
pathways - compete for APP as a substrate. In the former pathway, an initial cleavage of APP 
by α-secretase liberates a soluble peptide, APPsα (henceforth referred to as sAPPα). The 
remaining membrane-bound α-CTF fragment is further processed by γ-secretase to generate 
non-toxic P3 and AICD fragments. Conversely, the amyloidogenic pathway for APP 
processing involves an initial cleavage by β-secretase liberating a soluble peptide, APPsβ 
(henceforth referred to as sAPPβ). γ-secretase further processes the remaining β-CTF fragment 
to produce the toxic Aβ peptides along with AICD fragments (Figure 1). Though not discussed 
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in the present thesis, there may be additional APP processing pathways including one recently 
identified to involve η-secretase17.  
 
The physiological functions of APP-derived peptides are emerging rapidly and provide us with 
a more complete picture of the potential consequences of manipulating the APP processing 
pathways. 
 
1.3.1.1 sAPPα 
 
sAPPα is generated by α-secretase mediated cleavage of APP. The peptide is generally 
prescribed to be beneficial as it can protect neurons from oxygen-glucose deprivation and 
excitotoxicity18. Moreover, sAPPα promotes neurite outgrowth, synaptogenesis, cell adhesion 
and LTP11,19,20 as well as learning and memory in rodents when administered 
intracererebroventricularly21,22. Recent evidence further indicates the sAPPα can directly bind 
to and inhibit β-secretase cleavage of APP23. This finding suggests the existence of an 
endogenous positive feedback loop that can promote the non-amyloidogenic pathway over the 
amyloidogenic pathway for APP processing.  
Figure 1. Illustration of non-amyloidogenic and amyloidogenic pathways for APP processing.16 
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In patients genetically predisposed to developing AD, low levels of sAPPα in the cerebrospinal 
fluid (CSF) are observed and this correlates with poor performance on neuropsychological 
tests24. Although patients who develop AD sporadically have unaltered levels of sAPPα in their 
CSF25, there is a strong cumulative basis for enhancing sAPPα as a strategy for treatment of 
AD. However, owing to its large size, sAPPα is unable to cross the blood brain barrier 
effectively. Thus, increasing α-secretase activity is seen as the most direct and reasonable 
approach to increasing sAPPα levels26. 
 
The molecular identity of α-secretase remained elusive until 2010 when it was reported that 
ADAM10 is the main physiologically relevant α-secretase27. A quest for ADAM10 activators 
has begun, but it is important to remember that ADAM10 has multiple substrates including 
epidermal growth factor receptor ligands. Thus, strong widespread activation of ADAM10 may 
lead to tumor growth28. Given the existence of the aforementioned positive feedback loop 
involving sAPPα23, hyperactivation of ADAM10 may not be necessary in treatment of AD. 
 
1.3.1.2 P3 
 
The non-amyloidogenic processing of APP also liberates a P3 fragment (Figure 1). No clear 
biological role has been established for this fragment29. 
 
1.3.1.3 AICD 
 
The amino-terminal APP intracellular domain (AICD) is liberated after γ-secretase processing 
of APP in either the non-amyloidogenic or the amyloidogenic pathway (Figure 1). The 
resulting fragment is approximately 57-59 amino acids in length, but additional cleavage by 
other enzymes can lead to shorter fragments ranging from 31-50 amino acids in length29. AICD 
is thought to interact with proteins such as Fe65, translocate to the nucleus and function as a 
transcriptional activator of several genes (e.g. p53). Much is still unknown regarding the 
functions of AICD in the context of AD, but a comprehensive review can be found elsewhere30. 
 
1.3.1.4 sAPPβ 
 
The sAPPβ fragment is generated following β-secretase cleavage of APP (Figure 1) and 
appears to lack the neurotrophic effects associated with sAPPα31. Rather, it was linked to 
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disintegration of axons and pruning of synapses during development. sAPPβ performs this 
function by acting as a ligand to death receptor 6 and initiating caspase 6 signaling. 
Interestingly, withdrawal of neurotrophins induces production of sAPPβ and subsequent 
degeneration32.  
 
In APP(-/-)/APLP2(-/-) double knock-out mice, sAPPβ does not prevent perinatal lethality33. 
This is in contrast with sAPPα knock-in which results in viable double knock-out mice34. As 
such, the extra 16 amino acids at the C-terminus of sAPPβ point to key functional differences 
as compared to the shorter sAPPα fragment. These contrasting effects provide further 
motivation to pursue strategies that shift processing of APP towards the non-amyloidogenic 
pathway.  
 
1.3.1.5 Amyloid β 
 
Sequential cleavage by β-secretase and γ-secretase liberates Aβ peptides of varying lengths 
(Figure 1). The Aβ monomers can come together to form neurotoxic oligomers prior to 
formation of Αβ fibrils and amyloid plaque deposits. While Αβ40 is the predominant length 
produced via APP processing, Αβ42 is more prone to aggregation. This propensity for Aβ 
oligomers to aggregate have placed the peptide at the center of AD research. The current 
prevailing thought is that chronic imbalance in the production of Aβ relative to its clearance 
underlies the observed neurotoxicity in AD. Although the mechanisms for neurotoxicity are 
not fully understood, one hypothesis states that Aβ oligomers in the extracellular space can 
inhibit NMDA-mediated synaptic transmission and ultimately promote synapse loss3. This 
hypothesis has been further adapted to include oligomeric Αβ’s relationship to a number of 
receptors including AMPA receptors, LRP1 protein, α7 receptors and RAGE receptors35. As 
such, Aβ levels have been one of the most commonly used functional readouts in AD research. 
Importantly, although Αβ may be a valuable biomarker for clinical diagnosis, levels in the CSF 
are actually reduced in AD patients - not increased36. This likely reflects reduced clearance of 
Aβ through the CSF and, accordingly, accumulation in the brain.  
 
An increasing amount of attention is being given to the normal physiological functions of Aβ. 
Monomeric Aβ, for example, has neurotrophic and neuroprotective effects, can promote 
proliferation of neural progenitor cells and may be critical for synaptic function. These 
proposed functions are largely true when Aβ is present at low concentrations precluding 
formation of Aβ oligomers35. Therefore, delicate manipulation of APP processing pathways 
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may be a more advisable treatment strategy than strong perturbation of the amyloidogenic 
pathway. 
 
1.3.2 Subcellular Trafficking of APP 
 
The cellular trafficking of APP is heavily implicated in its processing. Under the canonical 
model (Figure 2), APP is synthesized in the endoplasmic reticulum and is transported to the 
Golgi Apparatus/Trans-Golgi Network (TGN) where it undergoes posttranslational 
modifications. The TGN is the major site of resident APP with just 10% of APP molecules 
being further transported to the plasma membrane via secretory vesicles37. APP which reaches 
the plasma membrane can be processed by α-secretase to generate sAPPα38. APP which is not 
processed and shed at the plasma membrane is internalized within minutes due to the presence 
of a “YENPTY” internalization motif at the C-terminus via clathrin-dependent endocytosis39. 
This internalization presents APP to endosomes where it can undergo β-secretase mediated 
processing and generate Aβ. Accordingly, inhibition of endocytosis can prevent β-secretase 
processing of APP40. Typically, increased delivery of APP to the surface or reduced 
internalization favors the non-amyloidogenic pathway for processing while enhanced retention 
in endosomes favors the amyloidogenic pathway for processing41.  
 
Figure 2. Illustration of the canonical APP trafficking model. APP leaves the Golgi and traffics down the axon (1) 
or, alternatively, traffics into an endosomal compartment (2). After insertion at the cell surface, some APP is re-
internalized into endosomes (3) where Aβ is produced. Endosomes can then recycle to the cell surface expelling 
Aβ (4). Alternatively, APP can also be transported from endosomes back to the Golgi (5). APP which is not 
internalized is subject to α-secretase cleavage at the cell surface expelling sAPPα (6).16  
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Once at endosomes, APP/APP-derived peptides (including Aβ) can be trafficked through other 
endocytic and recycling organelles to the Trans-Golgi Network, the cell surface or lysosomes 
for degradation37.  
 
1.3.3 Extracellular Vesicles 
 
It has been proposed that when the accumulation of Aβ is beyond the clearance capacity of 
lysosomes or glial cells, Aβ may be released into extracellular space and spread through the 
brain via extracellular vesicles42. Extracellular vesicles, including exosomes, are small vesicles 
(50-250 nm in diameter) which can be released from most cell types (including in the CNS) 
and participate in elimination of cellular waste, regulating immune responses and 
communicating between neural cells43–45. Notably, they can carry molecular content over long 
distances via bodily fluids. There are several categories of EVs based on their secretion 
pathways46,47: 
 
 Apopotosomes are released from cells undergoing apoptosis 
 Microvesicles can be relased by evagination of the plasma membrane 
 Exosomes can be released via fusion of multivesicular bodies (MVB) with the plasma 
membrane.  
 
Current methodologies are 
unable to distinguish between 
these categories and so they are 
collectively referred to as the 
EVs48. Because exosomes are 
released from MVBs, they are 
also a part of the endosomal-
lysosomal system (Figure 3). As 
such, the molecular contents of 
exosomes commonly consist of 
proteins that may have an 
endosomal past including 
tetraspanins, Rab GTPases, flotilin, 
Figure 3. Subcellular pathways for the packaging, lysosomal 
degradation and vesicular extrusion of damaged and 
aggregated proteins.46 
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Alix, TSG101, heat shock proteins49–52 as well as a variety of genetic material (e.g. DNA, 
mRNA, miRNA, rRNA)53–55. Although it is not clear what drives MVBs to fuse with plasma 
membranes (as opposed to trafficking cargo to lysosomes for degradation), inhibition of the 
lysosome pathway (e.g. with Bafilomycin A) enhances exosome secretion at the plasma 
membrane56. This finding suggests that EVs may function as an alternative disposal pathway 
to compensate for lysosomal dysfunction or in the event of misfolded protein overload57.  
 
Indeed, both Aβ and phosphorylated Tau - representing pathologically misfolded proteins in 
AD - can be found in EVs isolated from CSF, brain extracellular space and blood samples from 
AD patients58–60. Because these proteins have been demonstrated to inhibit autophagy flux and 
lysosomal function61, their release via exosomes may indicate a compensatory handling 
mechanism. In addition to handling intracellular Aβ, EVs have the ability to interact with and 
bind to Aβ extracellularly and thereby facilitate Aβ uptake by microglia62. These findings, 
cumulatively, provide support for the possibility of using EVs as biomarkers in disease 
diagnosis and treatment evaluation. Importantly, it is not clear whether EVs attenuate 
neurodegeneration or whether they can promote it. The notion and corresponding evidence that 
EVs may contribute to a prion-like spreading of Aβ63–65 is currently counterbalanced with 
evidence that EVs act as scavengers of Aβ66–68. Therefore, expanding our understanding of how 
EVs may be involved in extracellular aggregation and spread of Aβ could also aid in the 
development of AD therapeutics. Paper 4 of the present thesis aims to enhance our 
understanding of the contribution that EVs play in Aβ production and pathogenesis of AD.  
 
1.3.4 Synapses 
  
Neurons, as highly specialized cells, rely on synapses to propagate signals between cells. As 
such, synapse loss is expected to perturb communication across brain networks. In the context 
of AD, synapses are sites of early pathological changes and loss of synapses correlates with 
cognitive deficits69. The cause of this synaptic impairment is unclear, but proteolytic processing 
of APP is likely involved37 since synapses appear to be a major site for secretion of Aβ70,71 and 
oligomeric Aβ can dose-dependently decrease synaptic function, the number of synapses and 
impair memory72. Moreover, both β- and γ-secretase are present at synaptic terminals73,74. 
Despite this awareness, it remained unclear whether APP is trafficked to synapses for local 
processing or if the processing occurs elsewhere in neurons. This open question served as the 
motivation for Paper 1 of this thesis. 
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1.3.5 SNX Family of proteins 
 
Because endosomal trafficking and protein sorting (both at synapses as well as somatic 
compartments) is intimately connected to APP processing, a growing avenue of research aims 
to identify novel regulators for APP trafficking. Among these, several members of the sorting 
nexin (SNX) family have been demonstrated to regulate Aβ generation. SNXs are cytosolic or 
membrane-associated proteins which can be characterized by the presence of a phox-homology 
domain and a variable number of protein-protein interaction domains75,76. Collectively, they 
have been demonstrated to play key roles in the trafficking of protein cargo. Both positive and 
negative regulators of amyloidogenic processing of APP have been found among the SNX 
family. For example, SNX33 promotes α-secretase cleavage of APP77 while SNX27 influences 
Aβ generation by controlling the assembly of γ-secretase78. While there are over 30 members 
in the SNX family79, only a handful have been connected to APP processing. Paper 2 in this 
thesis provides evidence that a novel regulator, SNX3, can influence Aβ levels by altering APP 
internalization.  
 
1.3.6 Subcellular Trafficking of APP-relevant Secretases 
 
As the co-distribution of APP with α-, β- and γ-secretases dictates the nature of APP processing, 
considerable research has been conducted to understand trafficking of APP-relevant secretases 
as well.  
 
1.3.6.1 α-secretase 
 
In neural cells, α-secretase processing of APP is often connected with its localization at the 
plasma membrane80. However, it is also present and catalytically active in the TGN. The 
difference between these two processing sites may be related to constitutive versus regulated 
α-secretase activity. The latter has been shown to occur in the TGN in response to stimulation81 
and can lead to α-secretase activity beyond its constitutive level. For most α-secretase 
stimulators, it is is not clear whether they affect ADAM10 or other proposed α-secretases (e.g. 
ADAM9, ADAM17)82. The phorbol ester phorbol myristate acetate, for example, requires 
ADAM17 to activate α-secretase27 while the neuropeptide pituitary adenylate cyclase-
activating polypeptide stimulates α-secretase through ADAM1083. Activation of α-secretase 
through stimulators is primarily thought to occur via different signaling pathways including the 
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protein kinase C and MAPK pathways84. However, this underscores the possible contribution 
of α-secretase trafficking in regulation of its activity. Though little is known regarding the 
underlying mechanisms, α-secretase trafficking can - indeed - be controlled. Tetraspanins and 
nardilysin, for example, have been implicated in ADAM10 trafficking82. In primary neurons, 
short-term NMDA activation drives ADAM10 to the postsynaptic membrane through 
interaction with synapse-associated protein 9785. Moreover, an endoplasmic reticulum 
retention signal on the C-terminus of ADAM10 has now been identified to regulate its transport 
to the plasma membrane. These studies cumulatively suggest that trafficking of α-secretase to 
distinct subcellular locations may affect its catalytic efficiency.  
 
1.3.6.2 β-secretase 
 
It is well accepted that BACE1 is the main catalytically active β-secretase responsible for 
cleaving APP86. As such, it has been an attractive target for AD therapy. Indeed, BACE1 levels 
and activity are increased in the AD brain87 and downregulation of BACE1 in mice can inhibit 
Aβ generation88–91. It is synthesized in the ER and subsequently transported to the Golgi 
apparatus where it undergoes maturation. There, the pro-domain of BACE1 is removed by furin 
leading to a ~2-fold increase in activity92. BACE1 can then be transported to the plasma 
membrane or endosomal compartments. It is important to remember that BACE1 is rapidly 
internalized from the cell surface93, is predominantly intracellular89 and is active in acidic 
microenvironments94. Therefore, endosomes are viewed as the main β-secretase processing site 
for APP. Several proteins have been identified to regulate BACE1 trafficking. The GGA family 
of monomeric clathrin adaptor proteins, for example, can traffic BACE1 from endosomes. 
Phosphorylation within the DISL motif - at the cytoplasmic domain of BACE1 - promotes 
retrieval to the TGN95 whereas non-phosphorylated BACE1 is sent to the plasma membrane96. 
The sorting nexin (SNX) family of proteins are also involved in BACE1 trafficking. SNX6 
interaction with BACE1 retains the secretase in the endosome preventing transport to the 
TGN97 while SNX12 has been shown to regulate BACE1 trafficking between the cell surface 
and endosomes98. Interestingly, the endocytosis of APP and BACE1 appear to be spatially 
distinct involving a different class of endocytic vesicles. In contrast to APP, which is 
internalized through clathrin-dependent endocytosis, BACE1 is sorted from the plasma 
membrane to endosomes via a route controlled by the GTPase ADP ribosylation factor 6 
(ARF6)99. As a result, targeting distinct endosomal routes may be one valuable way to regulate 
BACE1 processing of APP. Indeed, an endosomally-targetted, sterol-linked BACE1 inhibitor 
took advantage of this differential subcellular compartmentalization and specifically inhibited 
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amyloidogenic processing of APP while permitting BACE1 processing of non-amyloid 
substrates100.  
 
1.3.6.3 γ-secretase 
 
Following cleavage by α- or β-secretase, APP can be further processed by γ-secretase. 
Presenilin, nicastrin, anterior pharynx-defective 1 and presenilin enhancer 2 come together to 
form a functional γ-secretase complex. Synthesis of the individual components and formation 
of the overall complex takes place in the ER and Golgi compartments101,102. Mature γ-secretase 
can then be transported to the plasma membrane where it can remain or be internalized into 
endosomes, multivesicular bodies or the lysosome103. Like both α- and β-secretase, γ-secretase 
trafficking relies on its interaction with a number of transport proteins. These proteins include 
Rab protein family members, PLD1, ARC, β2-adrenergic receptor, GPR3, β-arrestin 2, 
RER141. To discuss the relationship between all of these proteins and the various components 
of γ-secretase is beyond the scope of the presented thesis, but a comprehensive review103 can 
be consulted for further information.  
 
1.4 GENETICS 
 
The amyloid cascade hypothesis for AD pathogenesis is largely substantiated by a number of 
genetic studies. The APP gene is located on chromosome 21 and triplication of this 
chromosome - as is seen in Down’s Syndrome patients - yields three copies of the APP gene. 
This enhances APP expression and Aβ accumulation. Indeed, patients with Down’s Syndrome 
experience an early onset of AD pathology104. In addition to triplication of chromosome 21, 
inherited familial Alzheimer’s Disease (FAD) mutations in APP can cause early-onset Aβ 
deposition105. Most of these mutations are located near the α-, β- and γ-secretase cleavage sites 
and can be examined in depth on the Alzheimer Disease and Frontotemporal Dementia 
Mutation Database (http://www.molgen.ua.ac.be/ADmutations/). Importantly, a mutation in APP 
was discovered that appears to protect against AD and age-related cognitive decline. The 
mutation, A673T, is located near the BACE1 cleavage site and impairs BACE1 cleavage of 
APP106. This finding further supports the amyloid hypothesis of AD pathogenesis. Mutations 
in the presenilin gene have also been described and constitute the most severe forms of AD 
with complete penetrance and onset occurring as early as 30 years of age107. The mutations 
tend to alter the transmembrane domains of the PS1 and PS2 proteins and, as is the case with 
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APP mutations, these mutations have the shared effect of increasing the levels of Aβ42 relative 
to Aβ40108.  
 
Importantly, the aforementioned mutations in APP and presenilin are heavily implicated in 
early-onset AD (defined as occurring prior to 65 years of age), but this only represents ~1% of 
all AD cases. The majority of cases are late-onset and typically sporadic - involving no family 
history of AD107. The genetic basis of sporadic forms of AD remains enigmatic despite multiple 
genome wide association studies and attempts to identify novel risk factors. The best 
established risk factor, APOε4, is present in about 50% of late-onset AD patients109. Although 
carriers of two copies of the allele have 12 times the risk of developing late-onset AD compared 
to non-carriers (single copy carriers have 3 times the risk), APOε4 is neither necessary nor 
sufficient for development of AD thereby complicating its diagnostic utility110. Moreover, the 
mechanism by which APOε4 affects the risk of AD is not fully understood, but it is suggested 
to be involved in conversion of monomeric Αβ to more toxic, aggregative forms as well as in 
clearance of Aβ from the brain111.  
 
Although a number of additional risk genes have been identified for late-onset AD, they have 
weaker association to the disease as compared to APOε4. Taken together, there is likely a 
complex interplay between genetic and environmental factors which underlies development of 
sporadic forms of AD.  
 
1.5 ALTERNATIVES TO THE AMYLOID CASCADE HYPOTHESIS 
 
The “amyloid cascade hypothesis” described above in section 1.2.2 is the most popular 
hypothesis for AD-related neuropathologies and cognitive impairments. It holds that all other 
pathologies observed in patients are downstream events of excessive accumulation of Aβ. 
Although the presented thesis and constituent articles are built upon this hypothesis, it is 
important to acknowledge that multiple hypotheses for AD have been proposed. A few of these 
hypotheses are discussed briefly in this section. 
 
1.5.1 Tau Hypothesis 
 
The tau hypothesis is perhaps the most heavily investigated among the alternatives to the 
amyloid cascade hypothesis. In addition to senile plaques, neurofibrillary tangles were 
observed in the original characterization of AD brain over a century ago. However, the 
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molecular precursor to these tangles (i.e. hyperphosphorylated forms of the protein tau) was 
determined much later - in the 1980s112. Subsequently, a “tau hypothesis” was generated 
positing that tau phosphorylation and aggregation is the common denominator for the multitude 
of deleterious observations found in AD. The hypothesis draws support from both 
neurobiological studies113 as well clinical data114,115. Importantly, hyperphosphorylated tau in 
the brain and CSF correlates with the severity of dementia116,117 while Aβ plaques are 
considered a relatively poor correlate118. Tau, as a major component of the microtubule-
associated proteins, plays a critical role in stabilizing microtubules in axons. 
Hyperphosphorylation of tau is thought to disrupt this process ultimately leading to 
neurotoxicity119,120. The details of this mechanism are beyond the scope of this thesis, but can 
be reviewed elsewhere121.  
 
1.5.2 Oxidative Stress Hypothesis 
 
Oxidative stress refers to the imbalance between formation of reactive oxygen species (ROS) 
and the cell’s ability to clear them. Formed during oxidative phosphorylation by the electron 
transport chain in mitochondria, ROS interacts with a number of macromolecules. Excessive 
levels of ROS can place cells in a state of oxidative stress and lead to damage of the cell and 
its organelles. One prominent theory suggests that ROS is at the center of the normal aging 
process122. This theory extends to the AD research field as AD patients have high levels of 
oxidative damage123–126. ROS can have widespread effects on cells including to induce 
modifications to proteins. Such modifications may have the ability to promote 
neurodegeneration via protein misfolding127. It is not clear what causes the ROS imbalance 
observed in AD, but reviews can be consulted for in-depth characterization of molecular 
interaction partners and mechanisms126. 
 
1.5.3 Inflammation Hypothesis 
 
Presence of pro-inflammatory cytokines and activated complement factors has led to the idea 
that neuroinflammation is involved in the pathology of the disease. Though typically 
considered a downstream event to the amyloid hypothesis (with Aβ causing activation of 
microglia), neuroinflammation may exacerbate the course of disease128. On the other hand, 
polymorphisms in genes related to regulation of inflammatory processes offer a compelling 
explanation for sporadic forms of AD. IL-1 polymorphisms, for example, have been associated 
with differing degrees of microglial activation129. Moreover, APOε4 carriers with AD have 
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more microglial activation. Importantly, the mechanism of action for AD pathogenesis by 
microglial activation is still unclear, but epidemiological studies indicate that individuals 
receiving long-term anti-inflammatory therapy have a lower prevalence of AD130. 
 
1.5.4 Other Hypotheses 
 
In addition to the prominent hypotheses described above, vascular131, cholesterol132, metal133 
and cell cycle134 hypotheses have been proposed. To discuss all of these is well beyond the 
scope of this thesis, but the existence of so many hypotheses illustrates an important point. 
Namely that AD is a multifactorial disorder involving a litany of pathological events. As such, 
effective treatments will have to account for the diversity in events that precede 
neurodegeneration.  
 
1.6 TREATMENT STRATEGIES 
 
To date, only symptomatic medications have been approved by the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) for treatment of AD. These 
include acetylcholinesterase inhibitors (e.g. donepezil, galantamine, rivastigmine) and a partial 
NMDA receptor antagonist (i.e. memantine). Acetylcholinesterase inhibitors are used to 
elevate the level of acetylcholine at synapses counteracting the loss of cholinergic function and 
neurotransmission found in AD. Memantine, on the other hand, restricts glutamate-induced 
toxicity135. Under normal physiological conditions, NMDA receptors are blocked by 
magnesium ions. Strong glutamate signaling depolarizes the post-synaptic membrane and 
reverses the NMDA block allowing calcium ions to enter the postsynaptic neuron. In AD, 
however, constant glutamate stimulation and NMDA receptor over-activation is observed 
leading to dysfunction. Thus, memantine is thought to prevent excitotoxicity caused by 
excessive glutamate stimulation136. While these therapies have been shown to improve 
symptoms and may arrest the rate of cognitive decline, they do not prevent decline or reverse 
the neuronal damage seen in AD137. 
 
In light of results from genetic studies and the large body of evidence supporting the amyloid 
cascade hypothesis, the most attractive disease-modifying approaches have been to either 
disrupt aggregation, promote removal or prevent formation of Aβ. Compounds including 
glycosaminoglycan 3-amino-1-propaneosulfonic acid (3APS), colostrinin, scyllo-inositol and 
Zinc/Copper chelators have been used to prevent aggregation of Aβ. With the exception of 
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3APS, none of these agents have reached phase III of clinical trials. Disappointing results have 
since led to termination of the phase III clinical trial for 3APS138.  
 
Immunotherapy has been one of the most active areas of AD drug development despite an 
incomplete understanding of the mechanism behind amyloid clearance. Both active (i.e. 
vaccination) and passive immunization (i.e. monoclonal antibodies) approaches have been 
tested with varying levels of success. The first attempts at active immunization with Aβ1-42 
yielded promising preclinical results, but led to encephalitis during clinical trials and no 
improvement in cognition139. Vaccines have since been developed to limit encephalitic adverse 
events, but the variable antibody response seen in older patients has prompted investigation 
into passive immunization. Monoclonal antibodies designed to decrease plaque formation and 
enhance Aβ clearance, like Bapineuzumab (Janssen/Pfizer) and Solanezumab (Eli Lilly), have 
been tested140. However, in these notable cases, they did not meet their clinical endpoints for 
efficacy141,142. It was later determined by Positron Emission Tomography (PET) that nearly one 
quarter of all subjects lacked amyloid pathology at baseline and that this may underlie the 
failure to meet efficacy outcomes143. Recently, results from better-designed clinical trials of the 
human monoclonal antibody Aducanumab (Biogen), breathed new life into the passive 
immunization strategy for treatment of AD. Researchers reported a dose-dependent reduction 
in soluble and insoluble Aβ as well as a slowing of cognitive decline144. The drug has now been 
fast-tracked to phase III clinical trials145. 
 
In addition to immunization strategies to promote clearance of Aβ, considerable efforts have 
been placed on trying to prevent production of Aβ. These strategies have focused on inhibiting 
β- and γ-secretase, the enzymes responsible for producing Αβ through proteolytic processing 
of APP. BACE1, for example, has been viewed as a prime target for therapeutics. Initial 
challenges in crossing the blood brain barrier have been surmounted and BACE1 inhibitors are 
now being developed as small molecules inhibitors with favorable pharmacokinetic profiles. 
Emerging evidence also indicates that these inhibitors can reduce a number of biomarkers of 
amyloid load. However, one notable challenge that has plagued several BACE1 inhibitors 
during clinical trials has been their propensity to induce off-target toxicity146. This is likely due 
to the role of BACE1 in a number of functions including axon targeting146, myelination147, 
astrogenesis/neurogenesis148, synaptic plasticity148, maintaining spine density148 as well as 
processing of non-APP substrates like neuregulin 1148, neural cell adhesion molecule close 
homolog of L1 (CHL1)148 and the Notch-relevant Jagged 1 protein147. As a result, it is 
important to find an appropriate BACE1-inhibitor dose range where patients can balance 
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tolerable side-effects with the benefit of reducing Aβ sufficiently. Recently, a new class of 
BACE1 inhibitors have been proposed to take advantage of the subcellular distribution of 
BACE1-mediated APP processing. Preclinically, these inhibitors have been shown to reduce 
Aβ levels, but preserve BACE1 processing of non-APP substrates100. BACE1 inhibitors, 
though hindered by off-target effects, still hold promise for treatment in AD, but require further 
clinical validation148.  
 
Similar to BACE1, the γ-secretase complex has several non-APP substrates, including the 
Notch receptor 1. Attempts to inhibit γ-secretase have, accordingly, resulted in detrimental 
effects on cognition and functionality as was seen in phase III trials of Semagacestat (Eli 
Lilly)149. Notably, these trials did demonstrate a dose-dependant reduction in CSF Aβ150. 
Modulation of γ-secretase (as opposed to inhibition) has been proposed to reduce Aβ while 
circumventing the off-target consequence of strong inhibition.  
 
1.6.1 Exercise 
 
Epidemiological findings have suggested that exercise can reduce the risk of developing AD151. 
Consistently, a randomized controlled trial demonstrated that exercise can improve cognitive 
functioning in at-risk elderly individuals152. This exercise-induced improvement is likely a 
consequence of its actions on synapses. By affecting the number, function and structure of 
synapses, exercise can improve learning and memory which is prominently disrupted in AD153. 
Indeed, a recent clinical trial demonstrated the value aerobic exercise among early AD patients 
in improving functionality, memory and reducing hippocampal atrophy154.  
 
The molecular basis for these structural changes is not fully understood, but rodent-based 
experiments have provided several clues. Synaptic short- and long-term potentiation, for 
example, is increased in rats following voluntary running exercise155. Neurogenesis - which 
can result in newly formed synapses - is also enhanced after voluntary exercise156. In the 
hippocampus of adult rodents, exercise arrests neural stem cell division and drives 
differentiation into mature neurons. Electrophysiological measurements of these newly formed 
neurons indicates that the new synapses can integrate into functional circuits in the brain157. 
Moreover, exercise can protect neurons against excitotoxic and metabolic stress in 
experimental models of relevance to AD158–160. In transgenic mouse models of AD, exercise 
has been shown to ameliorate brain Aβ pathology and associated cognitive deficits161–164. The 
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underlying mechanisms for these benefits are unknown, but is a subject of interest in Paper 3 
of this thesis.  
 
Activation of neurons in response to exercise results in glutamate release leading to Ca2+ influx 
via post-synaptic NMDA receptor channels. While this Ca2+ influx promotes oxidative stress 
by increasing mitochondrial superoxide production, it also activates kinase pathways (e.g. 
CaMK2, MAPK) in order to mediate adaptive responses including strengthening of synapses 
and cellular stress resistance. Additionally, the stimulated pathways activate a number of 
transcription factors (e.g. CREB, NF-κB, AP-1) which are linked to neuronal plasticity and 
survival165. Among the number of genes which are upregulated in response to exercise is brain-
derived neurotrophic factor (BDNF)166. 
 
1.6.2 BDNF 
 
BDNF is widely expressed in the CNS by both neurons and glia. The precursor form, pro-
BDNF, is capable of binding to the low affinity p75 neurotrophin receptor (p75NTR) and 
promoting neuronal apoptosis148. Conversely, proteolytic processing by plasmin can convert 
pro-BDNF to mature BDNF, which - in turn - binds to the TrkB receptor and, thereby, promotes 
synaptogenesis and synaptic plasticity. As such, it plays a key function in learning and memory 
in the hippocampus. In AD, BDNF protein and mRNA levels are decreased167–176 and at least 
one BDNF gene polymorphism (i.e. Val66Met mutation) has been shown to have a positive 
association with AD pathogenesis177. Its value as a disease-modifying strategy in 
neurodegenerative disorders has, accordingly, been proposed177 and treatment with BDNF may 
protect against amyloid load178,179. However, the relationship between Aβ and BDNF remains 
unclear.  
 
One line of evidence suggests that the neuroprotective feature of BDNF can protect neurons 
against Aβ-induced neurotoxicity180. For example, BDNF can restore neuronal survival and 
growth after pre-treatment with Aβ. In mice, this has even led to improvements in spatial 
learning and memory181. The ability of BDNF to modulate synapses may directly underlie this 
improvement. BDNF can increase dendritic spine formation, enhance synaptic transmission181 
and is critically involved in induction and maintenance of LTP182–184. Indeed, treatment with 
exogenous BDNF can reverse LTP deficiencies caused by Aβ185. This may be due to BDNFs 
ability to stimulate autophosphorylation of NMDA and AMPA receptors and activate CamK2 
to protect synaptic function185. On the other hand, BDNF may alter the proteolytic processing 
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of APP179 though much is still unknown regarding this process. Paper 3 in this thesis aims to 
expand our understanding of this process.  
  21 
2 AIMS 
 
The overarching aim of the present thesis is to uncover mechanisms that regulate processing 
and trafficking of APP and APP-derived peptides. Presented below are the specific aims of 
constituent papers:  
 
2.1 PAPER 1: ENDOGENOUS APP ACCUMULATES IN SYNAPSES AFTER 
BACE1 INHIBITION 
 
To examine the fate of APP at neuronal synapses and the consequence of perturbing BACE1 
activity. 
 
2.2 PAPER 2: OVEREXPRESSION OF SNX3 DECREASES AMYLOID-Β 
PEPTIDE PRODUCTION BY REDUCING ENDOCYTOSIS OF AMYLOID 
PRECURSOR PROTEIN 
 
To examine the role of SNX3 in Aβ production and APP processing and trafficking. 
 
2.3 PAPER 3: EXERCISE AND BDNF REDUCE AΒ PRODUCTION BY 
ENHANCING Α-SECRETASE PROCESSING OF APP 
 
To uncover underlying mechanisms for how exercise mediates anti-amyloidogenic functions.  
 
2.4 PAPER 4: EXTRACELLULAR VESICLE-ASSOCIATED AΒ MEDIATES 
TRANS-NEURONAL BIOENERGETIC AND CA2+-HANDLING DEFICITS IN 
ALZHEIMER’S DISEASE MODELS 
 
To elucidate the contribution of extracellular vesicles to Aβ production and pathogenesis of 
AD.  
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER 1: ENDOGENOUS APP ACCUMULATES IN SYNAPSES AFTER 
BACE1 INHIBITION 
 
Synapse loss is a key pathological event in Alzheimer’s Disease that correlates strongly with 
cognitive deficits69. It is thought that proteolytic processing of APP plays a central role in both 
pre- and postsynaptic derangements37,186. Notably, synapses are a major site for Aβ release70, 
but β-cleavage of APP - unrelated to Aβ formation has also been implicated in synaptic 
impairment187–189. For this reason, APP processing in the context of synapses has been a subject 
of great interest. While trafficking and processing of APP has been studied extensively in non-
neuronal cells, its precise fate in neurons and neuronal synapses has been less clear. Notably, 
it has been difficult to determine the exact correlation between the behavior of expressed tagged 
APP constructs and endogenous APP in neurons and this has led to several competing 
hypotheses on the trafficking of APP to synapses99,190–192. In Paper 1, we address this problem 
by examining endogenous APP at hippocampal synapses. This was performed by combining a 
variety of immunocytochemical techniques with perturbation of β-secretase. 
 
Using antibodies directed to N-terminal APP epitopes (N-t1 and N-t2) as well as C-terminal 
APP epitopes (C-t1 and C-t2), immunocytochemical characterization was performed on 
primary neurons from mouse hippocampi. In neurons from BACE1(+/+) mice, APP N-
terminus labeling showed prominent overlap with synaptic markers (synaptotagmin and SV2). 
APP C-terminus labeling, on the other hand, was largely separated from synapses indicating 
that the synaptic APP pool consists of cleaved fragments. The effects of reduced BACE1 
activity were then examined using BACE(-/-) mice. The co-localization between N-terminus 
labeling and synaptic markers remained similar, but the peri-synaptic labeling of the C-
terminus was ameliorated (Figure 4). As such, C-terminus labeling colocalized with synaptic 
markers and this was confirmed through two distinct quantification methods. A thresholding 
quantification revealed that the percentage of C-terminus labeled synapses increased 1.84 times 
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using the C-t1 antibody and 
1.49 times using the C-t2 
antibody in neurons from 
BACE1(-/-) mice as 
compared to BACE(+/+) 
mice. A second 
quantification method 
involved comparing the 
intensity of APP C-terminus 
labeling in a region of 
interest fitting the synapse to 
that of peri-synaptic regions. 
The resulting synaptic 
intensity ratios for both C-t1 
and C-t2 were significantly 
higher in BACE1(-/-) 
neurons compared to 
BACE(+/+) neurons. This 
result suggests that the APP C-
terminus labeling is specifically 
enriched at the synapse in 
BACE1(-/-) neurons. These observations represent one of two possibilities in how APP is 
distributed at synapses: either N-terminal and C-terminal APP fragments co-exist at synapses 
or there is an increase in full-length APP levels at the synapses of BACE1-/- neurons. To 
provide insight into which one of these two possibilities was true, biochemical measurements 
were performed and indicated that the latter was likely true.  
 
Reducing Aβ production via pharmacological inhibition of BACE1 has been proposed as a 
therapeutic strategy in treatment of AD. As such, we repeated the immunocytochemical 
measurements in primary neurons isolated from rat hippocampi in the presence and absence of 
BACE1 inhibitor. In control neurons, APP N-terminus labeling was tightly co-localized with 
synaptic markers whereas APP C-terminus labeling was adjacent to synaptic regions. BACE1 
inhibitor treatment did not affect the distribution of APP N-terminus labeling, but did enhance 
colocalization of the APP C-terminus with synaptic markers. Thresholding quantification 
revealed a significantly higher percentage of synapses labeled with C-t1 and C-t2 compared to 
Figure 4. BACE1 deficiency induces co-accumulation of N-terminal and 
C-terminal APP epitopes in synaptic regions in mouse primary 
hippocampal neurons. (A) Double staining with synaptotagmin (tag) or 
SV2 antibodies and antibodies against the N-terminus of APP (N-t1, N-t2, 
upper panels) and C-terminus of APP (C-t1, C-t2, lower panels) in 
BACE1+/+ neurons. (B) Double staining with synaptotagmin or SV2 
antibodies and antibodies against the N-terminus of APP (N-t1, N-t-2, 
upper panels) and C-terminus of APP (C-t1, C-t2, lower panels) in 
BACE1−/− neurons. Scale bar = 2 μm.212 
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control neurons. Additionally, synaptic intensity ratios were significantly higher in BACE1 
inhibitor treated neurons as compared to control. Cumulatively, these findings are consistent 
with results obtained from BACE1-/- mice. 
 
To assess whether this C-terminus labeling shift can occur at the presynapse, we turned to 
proximity ligation assay (PLA) as the resolution of this technique allows distinction between 
the pre- and postsynaptic compartments. Antibodies directed towards APP C-terminus were 
ligated with antibodies directed towards presynaptic marker SV2. The resulting ligation was 
amplified producing a fluorescent signal. The number of PLA signals per synaptic region were 
then quantified - revealing a significant increase in PLA signals following BACE1 inhibition. 
Accordingly, this observation indicates that the APP C-terminus shift can occur 
presynaptically. 
 
Our findings, involving the study of endogenous APP in neurons, suggest that full-length APP 
can be trafficked through axons and targeted to synaptic vesicles of the presynapse. This is 
consistent with studies using APP constructs that have suggested that the enzymatic machinery 
needed for production of Aβ is operative in the presynaptic compartment193. Because the 
synapse is viewed as a critical site for Aβ release and synaptic loss is a key pathological event 
in AD, our findings provide support for targeting components of the presynaptic endosomal 
pathway in treatment of AD. An important implication of our observations is that part of the 
synaptic defects seen with potent BACE1 inhibitors194,195 may be due to accumulation of full-
length APP at the synapse.  
 
3.2 PAPER 2: OVEREXPRESSION OF SNX3 DECREASES AMYLOID-Β 
PEPTIDE PRODUCTION BY REDUCING ENDOCYTOSIS OF AMYLOID 
PRECURSOR PROTEIN 
 
Sorting nexins (SNXs) have diverse functions in protein sorting and membrane trafficking. A 
single nucleotide polymorphism in SNX3 was recently found to be associated with AD196. 
However it remains unknown how SNX3 participates in Aβ production. In Paper 2, we explore 
this open question by studying the behavior of APP in response to SNX3 overexpression in 
human embryonic kidney cell line 293T (HEK293T).  
 
Using the highly sensitive and specific MesoScale Discovery multiplex ELISA system, we 
found that SNX3 overexpression together with APP in HEK293T cells significantly reduced 
the levels of both secreted Aβ40 and Aβ42. Moreover, the SNX3 overexpression also decreased 
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sAPPβ levels in cell culture media. These findings cumulatively suggest that SNX3 
overexpression reduces amyloidogenic processing of APP. 
 
To understand the mechanism for this reduction, we sought to understand the relationship 
between APP and BACE1 in intact cells. To this end, a bimolecular fluorescence 
complementation (BiFC) assay was used. APP was tagged with the non-fluorescent N-terminal 
fragment of the Venus protein (VN), while BACE1 is tagged with the non-fluorescent C-
terminal fragment of the Venus protein (VC). When APP and BACE1 are in close proximity, 
VN and VC come together to form a functional Venus protein that produces a fluorescent 
signal. Our results indicate that overexpression of SNX3 caused a significant reduction of the 
interaction between APP and BACE1.  
 
Because many lines of evidence suggest that endosomes are the critical site for BACE1-
mediated processing of APP, we tested whether SNX3 overexpression led to an inhibition of 
APP endocytosis. To this effect, APP was N-terminally tagged with an α-bungarotoxin-binding 
site (BBS). Endocytosis of APP was investigated by incubating cell surface BBS-APP with 
Alexa Fluor 555-conjugated α-bungarotoxin. Compared to control cells, overexpression of 
SNX3 significantly reduced APP internalization (Figure 5). Accordingly, it would be expected 
that SNX3 overexpression would 
lead to enhanced APP levels at the 
cell surface. To test this 
possibility, cell surface APP 
levels were determined by flow 
cytometry. Indeed, SNX3 
overexpression led to an increase 
in the percentage of cells labeled 
with surface APP. These results, 
cumulatively, suggest that SNX3 
regulates Aβ production by 
mediating internalization of APP 
from the surface to intracellular 
processing organelles.  
 
Our findings are consistent with 
previous studies suggesting that SNX3 
Figure 5. Overexpression of SNX3 inhibits endocytosis of APP. 
HEK293T cells were co-transfected with empty vector (A) or 
SNX3 (B) and BBS-APP, and endocytosis of cell surface APP 
was examined. Scale bar = 10 µm. 
A 
B 
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is involved in endocytosis of cargo molecules197,198. Although the precise role of SNX3 in 
endocytosis is unclear, our findings provide evidence that it can incluence APP endocytosis 
and, as such, may be a putative target in AD treatment research. Moreover, previous studies 
have also demonstrated that a close homolog of SNX3, SNX12, regulates Aβ production by 
affecting endocytosis of BACE198. Thus, there may be distinct sorting pathways for APP vs. 
APP-relevant secretases. Targeting SNXs would, therefore, be particularly appealing if it 
reduces amyloidogenic processing of APP whilst leaving BACE1 processing of non-APP 
substrates intact. 
 
3.3 PAPER 3: EXERCISE AND BDNF REDUCE AΒ PRODUCTION BY 
ENHANCING Α-SECRETASE PROCESSING OF APP 
 
Epidemiological findings suggest that regular exercise can reduce the risk of AD, and studies 
in AD mouse models have demonstrated that running wheel exercise can reduce Aβ 
accumulation and ameliorate cognitive deficits165,199. Despite these findings, the underlying 
cellular and molecular mechanisms are unknown. A large body of evidence suggests that brain-
derived neurotrophic factor (BDNF) regulates key adaptive responses with regards to exercise. 
These responses include neurogenesis, synapse formation, learning and memory, and neuronal 
stress resistance - many of which are perturbed in the pathological AD state200,201. Indeed, AD 
patients have lower levels of mature BDNF compared to age-matched control subjects173. 
Cumulatively, these findings highlight the therapeutic potential of BDNF in treatment of AD 
despite the fact that it is not clear exactly how BDNF affects APP processing. Paper 3 of this 
thesis aims to address these open questions by examining the relationship between exercise, 
BDNF and APP processing in AD mice as well as neural cells.  
 
To test whether a relatively short 3-week period of exercise is sufficient to reduce Aβ levels in 
AD mice, a voluntary running wheel experiment was performed. Following 3 weeks, 
hippocampi from runner mice and sedentary control mice were isolated. Aβ40 and Αβ42 levels 
were then measured in these samples using the highly sensitive and specific MesoScale 
Discovery multiplex ELISA system. We found significant reduction in both Aβ isoforms in 
exercising mice compared to sedentary controls. Moreover, we found that sAPPα levels were 
also increased in exercising mice. Cumulatively, these observations indicated that exercise 
shifts the processing of APP to favor the non-amyloidogenic pathway. Because BDNF is 
considered a prominent mediator of exercise-induced effects, including in counteracting 
neurodegenerative processes in animal models of AD, we turned our attention to BDNF. 
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Indeed, in our exercising mice, BDNF levels were elevated approximately 2-fold in comparison 
to sedentary control mice (Figure 6).  
 
To test whether BDNF itself can recapture the Aβ observations seen with exercise, we treated 
human SHSY5Y neural cells with BDNF. As was seen with exercise, levels of secreted Aβ40 
and Αβ42 in culture media were significantly reduced compared to control. Therefore, it 
appears that BDNF is able to suppress amyloidogenic load - though the mechanism is unclear. 
We hypothesized that BDNF reduces Aβ through modulation of the α-secretase enzyme. To 
test this hypothesis, an α-secretase inhibitor was used alone and in combination with BDNF 
treatment. Treatment with α-secretase inhibitor significantly increased secreted Aβ levels 
compared to control cultures. Importantly, in cultures co-treated with α-secretase inhibitor and 
BDNF, Aβ levels were significantly higher than control cultures. Moreover, BDNF treatment 
enhanced sAPPα levels. Taken together, these results indicate that BDNF likely reduces Αβ 
levels by enhancing α-secretase activity.  
 
The subcellular localization of α-secretase plays a role in its proteolytic ability to process APP. 
Because the cell surface is thought of as the primary site for α-secretase processing of APP, we 
Figure 6. Exercise shifts APP processing towards the non-amyloidogenic pathway. 3 weeks of 
voluntary running wheel exercise among AD mice significantly lowered hippocampal Aβ40 
(A) and Aβ42 (B) levels while significantly raising sAPPα (C) and BDNF (D) levels compared 
to sedentary control mice.213 
  29 
hypothesized that BDNF increases the amount of α-secretase on the cell surface. Using flow 
cytometry, we found that BDNF treatment actually resulted in reduced cell-surface α-secretase. 
This surprising finding supports the notion that regulated α-secretase activity occurs 
intracellularly while constitutive α-secretase activity occurs at the cell surface202. Indeed 
cellular levels of sAPPα were enhanced in BDNF treated cultures compared to control. 
 
Although sAPPα has been linked to neurite outgrowth19, it is not clear whether BDNF utilizes 
the peptide to carry out its neurotrophic functions. To test the hypothesis that BDNF promotes 
neurite outgrowth through enhanced sAPPα production, SHSY5Y neural cells were cultured 
in a manner to produce a homogenous population of neuronally differentiated cells. A 
fluorescence based neurite outgrowth assay was used in conjunction with BDNF and α-
secretase inhibitor treatment. BDNF resulted in significant enhancement of neurite outgrowth 
compared to control cultures. However, BDNF and α-secretase inhibitor co-treatment did not 
significantly alter neurite outgrowth as compared to cultures treated with BDNF alone. This 
finding indicates that there are likely multiple mechanisms by which BDNF promotes neurite 
outgrowth and enhancement of α-secretase is likely only a minor contributor. 
 
BDNF has been proposed as a therapeutic in AD primarily due to its ability to promote neuronal 
survival and neurite outgrowth. However, our work also suggests its value as a prophylactic. 
By regulating α-secretase activity, BDNF plays an important role in determining the fate of 
APP with regards to APP processing pathways. Importantly, sAPPα has recently been shown 
to bind to and inhibit BACE1203. This finding suggests the presence of an endogenous 
autoregulatory positive feedback loop to promote non-amyloidogenic processing of APP and 
our study provides a scenario for this to happen. Taking advantage of such a loop, for example 
via BDNF, might offer a compelling prophylactic strategy in treatment of AD as it would likely 
limit off-target adverse events traditionally seen with BACE1 inhibitors. Because BDNF may 
have low blood-barrier penetration and poor biostability204, it is important to identify factors 
that influence BDNF production in vivo. Exercise, which enhances BDNF in brain cells, is 
therefore an attractive approach for increasing α-secretase activity in the fight against AD. 
 
3.4 PAPER 4: EXTRACELLULAR VESICLE-ASSOCIATED AΒ MEDIATES 
TRANS-NEURONAL BIOENERGETIC AND CA2+-HANDLING DEFICITS IN 
ALZHEIMER’S DISEASE MODELS 
 
It has recently been suggested that pathogenic forms of Aβ can propagate between cells in a 
prion-like manner. Thus, the misfolded protein is thought to pass from donor to recipient cell 
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where it can function as a seed for further aggregation205,206. The mechanisms for this 
propagation is, however, unclear207. Extracellular vesicles (EVs), including exosomes, 
represent one potential mechanism by which pathogenic protein can be spread throughout the 
brain. Multivesicular bodies, being a part of the endosomal system, have been reported as an 
important site for Aβ generation and, for this reason, EVs may also be a site of APP processing 
into Aβ58,208. Paper 4 of the present thesis aims to expand our understanding of the contribution 
of ΕVs to Aβ production and AD pathogenesis.  
 
We first isolated EVs from the cell media of H4 glioblastoma cell lines expressing either a 
pathogenic presenilin mutation or wildtype presenilin according to established guidelines48. Aβ 
levels were then measured using the MesoScale Discovery multiplex ELISA system. We found 
that while both Aβ40 and Αβ42 were significantly lower in the EVs compared to the EV-
depleted media, the Aβ42/Αβ40 ratio in EVs was significantly higher than in EV-depleted 
media. This holds particular relevance as the Aβ42/Αβ40 ratio is considered a better predictor 
of AD than individual concentrations of Aβ isoforms209,210. Similar Aβ results were obtained 
when isolating exosomes released by human neurons derived from induced pluripotent stems 
cells of an AD patient carrying a pathogenic presenilin mutation compared to cells from a 
normal human subject. By treating EVs with trypsin, we tested whether Aβ is associated to the 
outer surface membrane of EVs or contained within EVs. A reduction in both Aβ40 and Αβ42 
following trypsin treatment suggests that Aβ binds to the surface of EVs. Notably, our results 
indicates that this association with the EV surface likely occurs prior to EV release from cells.  
 
Because Aβ production is intimately linked to the endosomal system, we hypothesized that 
inhibiting the lysosome would increase the release of Aβ42-containing EVs from 
multivesicular bodies to the extracellular space. Indeed, incubating H4 cells with an inhibitor 
of lysosomal function (bafilomycin A) increased EV secretion as well as the EV Aβ42/Aβ40 
ratio. This holds particular relevance as lysosomal dysfunction has previously been shown to 
occur in AD patients211. 
 
To examine whether these EVs derived from cells containing pathogenic presenilin mutation 
are neurotoxic, EVs were isolated from H4 culture media and added to the media of primary 
rat cortical neurons. Significant reduction in neuronal viability occurred within 48 hours and 
the cells were more sensitive to glutamate-induced excitotoxicity. Moreover, treatment of 
primary neurons with EVs derived from H4 cells with pathogenic presenilin mutations resulted 
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in perturbed Ca2+ handling capacity as well mitochondrial impairment. Collectively, these 
events may lead to the observed neurotoxicity. 
 
To determine whether EVs isolated from AD patients and animal models exhibit the same 
neurotoxic properties as EVs isolated from cell cultures, the levels of EV Aβ40 and Αβ42 were 
determined from the plasma of AD mice and CSF of AD patients. In both cases, the levels of 
each individual Aβ isoform in EVs was lower than in EV-depleted plasma/CSF. However, as 
was the case with results from cell culture, there was a significantly higher Aβ42/Αβ40 ratio in 
EVs compared to the EV-depleted control fractions. CSF-derived EVs from AD patients were 
then incubated with cultured cortical neurons and underwent a battery of tests to examine 
neurotoxicity. Significant reduction in neuronal viability, increase in vulnerability to 
glutamate-induced excitotoxicity, enhanced Aβ aggregation and apoptosis, perturbed Ca2+ 
handling capacity and reduced mitochondrial respiration were observed.  
 
Cumulatively, these findings highlight the potential role of EVs in propagating Aβ-related 
pathology and associated neuronal degeneration. Notably, EV-mediated neurotoxicity is likely 
the consequence of heightened Aβ42/Αβ40 ratio at the surface of EVs rather than the 
concentration individual Aβ isoforms. In view of the fact that lysosome dysfunction is 
increased in AD patients, EVs may represent a compensatory mechanisms for handling 
amyloid load. Moreover, amyloid overload may promote cells to use EVs as a mechanism for 
disposing intracellular Aβ and, accordingly, lessen the burden on lysosomes. While this may 
lessen the amyloid burden on the cell, neighboring cells may be exposed to EV-induced 
neurotoxicity. As such, targeting Aβ-laden EVs may hold potential as an AD therapeutic.  
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
This thesis provides insight into mechanisms which regulate amyloid precursor protein 
processing and trafficking. Paper 1 determines that endogenous full-length APP is - in fact 
- capable of trafficking to presynaptic nerve terminals and accumulates upon BACE1 
perturbation. This observation highlights the importance of monitoring synaptic response 
when developing BACE1 inhibitors to prevent off-target toxicity. Paper 2 identifies a novel 
protein, SNX3, which is capable of transporting APP and, thereby, regulates amyloidogenic 
processing. Further validation - both in primary neuronal cells and in AD animal models - 
may provide insight into whether this could serve as a suitable target in AD therapy. Paper 
3 concludes that exercise and BDNF can reduce toxic Aβ production by enhancing α-
secretase processing of APP. This enhancement appears to be the consequence of α-secretase 
distribution and may offer a scenario for an endogenous autoregulatory feedback loop to 
commence and, accordingly, suppress amyloidogenesis. Exercise and BDNF may, therefore, 
be capable of “jump-starting” the cellular proteolysis system in a fashion to correct 
pathogenic mechanisms in AD. Paper 4 concludes that extracellular vesicles in AD relevant 
models carry a higher ratio of Aβ42/Αβ40 than their surroundings and can induce 
neurotoxicity of neighboring cells. In light of this, extracellular vesicles are currently being 
explored for their diagnostic utility as well as a method for understanding how amyloidogenic 
propagation can occur within the brain.  
 
While all 4 papers hold value in the development of AD therapeutics, Paper 3 is one that can 
have near-immediate implications and would be my personal choice for furtherment. 
Although it is apparent that both exercise and BDNF have beneficial effects in reducing Aβ 
through enhancement of the non-amyloidogenic pathway for APP processing, it would be 
interesting to identify whether the key regulator for exercise-induced Aβ effects is, in fact, 
BDNF. To this effect, in vivo running experiments involving AD mice with perturbed BDNF 
signaling could offer additional support. Moreover, sedentary AD mice treated with 
BDNF/BDNF mimetics/trkB agonist could open the door for an exciting class of novel 
biopharmaceutical drugs.  
 
Clinical trials have demonstrated the value of exercise as a strategy in fighting AD-related 
impairments and the start-up costs of such strategies are considerably lower than drug 
development. As such, I believe promoting exercise among at-risk individuals to be an 
exciting approach in alleviating AD symptoms. Though exercise is traditionally well-
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regarded in its ability to fight - for example - weight gain and heart disease, its benefit in 
memory and cognition is becoming increasingly difficult to ignore. Education regarding the 
neurobiological benefits of exercise should, therefore, be a salient goal for both scientists and 
healthcare providers worldwide. 
 
The UK-based National Health Service estimates that people aged over 65 years, on average, 
spend 10 or more hours a day sitting/lying down making them the most sedentary age group. 
As such, they describe inactivity as a “silent killer” for the generation. Because physical 
limitations among this age group may hinder participation in traditional forms of exercise, an 
interesting avenue of further research involves comparison between different exercise 
modalities in their propensity to help in AD. For example, while running may place a 
heightened demand on bones and joints, swimming could serve as a more suitable, low-
impact alternative. Collaboration between physicians, physical therapists and basic research 
scientists could help in design of tailored regimens that are effective both prophylactically 
and therapeutically in the context of AD.   
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